Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 10/20 | 0.50 |
| ▸ | CASP3 | P42574 | 10/20 | 0.43 |
| ▸ | CASP6 | P55212 | 5/20 | 0.43 |
| ▸ | CASP8 | Q14790 | 5/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10248110 | 1.00 | CASP1 (0.50) | CASP1CASP3CASP6CASP8 | |
| SCHEMBL10284689 | 0.93 | CASP3 (0.46) | CASP1CASP3CASP6CASP8 | |
| SCHEMBL10268213 | 0.93 | CASP3 (0.46) | CASP1CASP3CASP6CASP8 | |
| SCHEMBL10248117 | 0.90 | CASP1 (0.46) | CASP1CASP3CASP6CASP8 | |
| SCHEMBL10199551 | 0.90 | CASP1 (0.46) | CASP1CASP3CASP6CASP8 | |
| SCHEMBL10199583 | 0.90 | CASP3 (0.46) | CASP1CASP3CASP6CASP8 | |
| SCHEMBL10247770 | 0.90 | CASP3 (0.46) | CASP1CASP3CASP6CASP8 | |
| SCHEMBL10247795 | 0.89 | CASP3 (0.44) | CASP1CASP3CASP6CASP8 | |
| SCHEMBL10199755 | 0.89 | CASP3 (0.44) | CASP1CASP3CASP6CASP8 | |
| SCHEMBL646695 | 0.87 | CASP1 (0.68) | CASP1CASP3CASP6CASP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165319-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-28 | — | — | US | disclosed |
| US-20120165319-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-28 | — | — | US | disclosed |
| US-7790713-B2 | Inhibitors of interleukin-1β converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-09-07 | — | — | US | disclosed |
| US-7790713-B2 | Inhibitors of interleukin-1β converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-09-07 | — | — | US | disclosed |
| US-20080039449-A1 | Inhibitors of interleukin-1beta converting enzyme | BATCHELOR MARK J | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165319-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | IL1A, IFNAR1, IL1B | CASP1 6/4885CASP3 85/4885CASP6 89/4885 |
| US-20080039449-A1 | Inhibitors of interleukin-1beta converting enzyme | IL1A, IL1B, IFNAR1 | CASP1 5/4885CASP3 67/4885CASP6 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.